What is Micro Interventional Devices?
Micro Interventional Devices (MID) is at the forefront of developing and commercializing cutting-edge catheter-based solutions designed to treat structural heart disease. Their primary innovation, the MIA-T Percutaneous Tricuspid Annuloplasty System, represents a significant leap forward, offering a minimally invasive alternative to conventional open-heart surgery. This approach not only benefits patients by reducing recovery times and risks but also streamlines procedures for surgeons and optimizes resource utilization for healthcare networks. MID's commitment to advancing TCR technologies aims to improve the quality of life for individuals suffering from cardiac conditions.
How much funding has Micro Interventional Devices raised?
Micro Interventional Devices has raised a total of $24.3M across 6 funding rounds:
Private Equity
$250K
Debt
$100K
Series B
$3.5M
Series D
$20M
Debt
$150K
Debt
$262K
Private Equity (2012): $250K with participation from The Life Sciences Greenhouse of Central Pennsylvania
Debt (2012): $100K led by Ben Franklin Technology Partners of Northeastern Pennsylvania
Series B (2013): $3.5M supported by Battelle Ventures, LP and Originate Ventures
Series D (2019): $20M featuring OSCOR
Debt (2020): $150K backed by PPP
Debt (2021): $262K with participation from PPP
Key Investors in Micro Interventional Devices
Ben Franklin Technology Partners of Northeastern Pennsylvania
Ben Franklin Technology Partners of Northeastern Pennsylvania is dedicated to fostering technological innovation and economic development within the region, providing crucial early-stage capital and strategic support to technology-focused companies.
The Life Sciences Greenhouse of Central Pennsylvania
The Life Sciences Greenhouse of Central Pennsylvania is an evergreen venture fund committed to advancing healthcare through early-stage capital and operational expertise for life sciences technologies, aiming to strengthen the Pennsylvania life sciences ecosystem.
Originate Ventures
Originate Ventures is an early-stage venture capital firm based in Pennsylvania, focusing on investing in and providing entrepreneurial guidance to emerging companies, particularly within Pennsylvania and New Jersey.
What's next for Micro Interventional Devices?
With the recent infusion of major strategic capital, Micro Interventional Devices is poised for significant expansion and further innovation in the structural heart disease market. The company's focus on developing less invasive, catheter-based technologies aligns with the growing trend in interventional cardiology towards patient-friendly procedures. This substantial backing will likely fuel further research and development, clinical trials, and the scaling of manufacturing capabilities to meet increasing demand. MID's strategic positioning and technological advancements suggest a trajectory towards becoming a key player in the rapidly evolving field of transcatheter cardiac repair, potentially leading to further growth and market penetration.
See full Micro Interventional Devices company page
